Drugs / ATV-1601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07038369 | Jul 2025 → Aug 2028 expected | cervical carcinoma, endometrial carcinoma, estrogen-receptor positive breast cancer, fallopian tube cancer +3 | Atavistik Bio, Inc | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07601425 | Jul 2026 → Dec 2027 expected | hereditary hemorrhagic telangiectasia | Atavistik Bio, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Atavistik Bio, Inc | Regulatory Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) atavistikbio.com ↗
The FDA’s clearance of the Harmony-HHT Phase 1/2 study design allows Atavistik Bio to leverage existing clinical data with ATV-1601 and proceed directly into a randomized study. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATV-1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038369 ↗ |
| Action | Inhibit | “Selective AKT1 E17K Allosteric Inhibitor” NCT07038369 ↗ |
| Route | Oral | “ATV-1601 administered orally” NCT07038369 ↗ |
| Target | AKT1 | “Selective AKT1 E17K Allosteric Inhibitor” NCT07038369 ↗ |